Read More

atai Life Sciences And Massachusetts General Hospital Announce Initiation Of Clinical Study Investigating Neuroplasticity Biomarkers In Treatment-Resistant Depression Patients Undergoing Ketamine Treatment

atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has initiated a clinical study

ATAI

Read More

Reported Late Wednesday, Ardelyx Announces FDA Advisory Committee Votes 9-To-4 That The Benefits Of XPHOZAH Outweigh Its Risks For The Control Of Serum Phosphorus In Adult Patients With Chronic Kidney Disease On Dialysis

The Advisory Committee voted 9:4 in favor of XPHOZAH as a monotherapy and 10:2 in favor of XPHOZAH in combination with phosphate binders The Office of New Drugs is expected to provide a response to Ardelyx's appeal

ARDX